At a Glance
Therapeutic Area:
Relapsing forms of multiple sclerosis (MS)
Approved Applications:
Tysabri® (natalizumab) is a prescription medicine used to treat adults with relapsing forms of multiple sclerosis (MS) to slow the worsening of symptoms common in people with MS and to decrease the number of flare-ups (relapses). MS is a progressive disease that causes damage to the central nervous system, manifested in outward and silent symptoms. Although there is no cure for MS, many treatments are available that can help slow progression of the disease.
Applications In Development:
Acquisition Date:
February 2017
Royalty Seller:



"Today’s announcement is the result of Perrigo’s review of strategic alternatives for the Tysabri royalty stream announced in November 2016. We are pleased to have reached an agreement that maximizes the value of this non-core asset. This transaction furthers our stated strategy to enhance our portfolio and focus on our consumer-facing and Rx businesses. This is a meaningful step in our portfolio review process and I am confident that the Board and management will focus on creating value for shareholders."

John T. Hendrickson, CEO Perrigo
© 2014 Royalty Pharma, RP Management LLC. All Rights Reserved.